In:
The Journal of Infectious Diseases, Oxford University Press (OUP), Vol. 228, No. 7 ( 2023-10-03), p. 895-906
Abstract:
Anticoagulation (AC) utilization patterns and their predictors among hospitalized coronavirus disease 2019 (COVID-19) patients have not been well described. Methods Using the National COVID Cohort Collaborative, we conducted a retrospective cohort study (2020–2022) to assess AC use patterns and identify factors associated with therapeutic AC employing modified Poisson regression. Results Among 162 842 hospitalized COVID-19 patients, 64% received AC and 24% received therapeutic AC. Therapeutic AC use declined from 32% in 2020 to 12% in 2022, especially after December 2021. Therapeutic AC predictors included age (relative risk [RR], 1.02; 95% confidence interval [CI] , 1.02–1.02 per year), male (RR, 1.29; 95% CI, 1.27–1.32), non-Hispanic black (RR, 1.16; 95% CI, 1.13–1.18), obesity (RR, 1.48; 95% CI, 1.43–1.52), increased length of stay (RR, 1.01; 95% CI, 1.01–1.01 per day), and invasive ventilation (RR, 1.64; 95% CI, 1.59–1.69). Vaccination (RR, 0.88; 95% CI, 84–.92) and higher Charlson Comorbidity Index (CCI) (RR, 0.98; 95% CI, .97–.98) were associated with lower therapeutic AC. Conclusions Overall, two-thirds of hospitalized COVID-19 patients received any AC and a quarter received therapeutic dosing. Therapeutic AC declined after introduction of the Omicron variant. Predictors of therapeutic AC included demographics, obesity, length of stay, invasive ventilation, CCI, and vaccination, suggesting AC decisions driven by clinical factors including COVID-19 severity, bleeding risks, and comorbidities.
Type of Medium:
Online Resource
ISSN:
0022-1899
,
1537-6613
DOI:
10.1093/infdis/jiad194
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2023
detail.hit.zdb_id:
1473843-0
Bookmarklink
